X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DIVIS LABORATORIES AJANTA PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 20.7 33.6 61.7% View Chart
P/BV x 4.8 5.5 87.2% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 AJANTA PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
DIVIS LABORATORIES
Mar-17
AJANTA PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,8181,222 148.8%   
Low Rs1,106784 141.1%   
Sales per share (Unadj.) Rs239.5153.1 156.4%  
Earnings per share (Unadj.) Rs52.839.9 132.2%  
Cash flow per share (Unadj.) Rs59.544.6 133.4%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs230.0201.8 114.0%  
Shares outstanding (eoy) m88.77265.47 33.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.16.6 93.2%   
Avg P/E ratio x27.725.1 110.3%  
P/CF ratio (eoy) x24.622.5 109.2%  
Price / Book Value ratio x6.45.0 127.9%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m129,782266,266 48.7%   
No. of employees `0006.89.7 69.8%   
Total wages/salary Rs m3,7654,687 80.3%   
Avg. sales/employee Rs Th3,128.44,175.0 74.9%   
Avg. wages/employee Rs Th554.0481.5 115.1%   
Avg. net profit/employee Rs Th689.71,089.3 63.3%   
INCOME DATA
Net Sales Rs m21,25840,643 52.3%  
Other income Rs m242749 32.3%   
Total revenues Rs m21,49941,392 51.9%   
Gross profit Rs m6,58414,460 45.5%  
Depreciation Rs m5961,233 48.3%   
Interest Rs m423 18.1%   
Profit before tax Rs m6,22613,953 44.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5393,349 46.0%   
Profit after tax Rs m4,68610,604 44.2%  
Gross profit margin %31.035.6 87.1%  
Effective tax rate %24.724.0 103.0%   
Net profit margin %22.026.1 84.5%  
BALANCE SHEET DATA
Current assets Rs m12,23640,105 30.5%   
Current liabilities Rs m3,4616,595 52.5%   
Net working cap to sales %41.382.5 50.1%  
Current ratio x3.56.1 58.1%  
Inventory Days Days60119 50.8%  
Debtors Days Days8481 104.7%  
Net fixed assets Rs m11,14019,995 55.7%   
Share capital Rs m177531 33.3%   
"Free" reserves Rs m20,23753,043 38.2%   
Net worth Rs m20,41453,574 38.1%   
Long term debt Rs m100-   
Total assets Rs m24,48661,585 39.8%  
Interest coverage x1,519.4618.4 245.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.7 131.5%   
Return on assets %19.217.3 111.0%  
Return on equity %23.019.8 116.0%  
Return on capital %30.526.1 116.9%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m11,66735,384 33.0%   
Fx outflow Rs m1,61610,399 15.5%   
Net fx Rs m10,05224,985 40.2%   
CASH FLOW
From Operations Rs m2,85411,493 24.8%  
From Investments Rs m-2,604-11,372 22.9%  
From Financial Activity Rs m-2-93 2.1%  
Net Cashflow Rs m24828 873.6%  

Share Holding

Indian Promoters % 73.8 52.0 141.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 11.8 13.1%  
FIIs % 7.6 19.0 40.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.2 98.8%  
Shareholders   20,968 31,796 65.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  PANACEA BIOTECH  

Compare AJANTA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Trade War Fears; Widening of Trade Deficit and Top Stocks in Action Today(Pre-Open)

Indian share markets trimmed their day's losses and ended flat on Friday amid weakness in their Asian peers, that wobbled on Friday as investors braced for US tariffs against China.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 15, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS